Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma
NCT07631325Phase 2Recruiting
- Start
- Nov 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of axelopran in cutaneous melanoma (CM). Started Nov 2026; status: recruiting.
02
Drugs
axelopran
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT07631325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07631325.